title: Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum.
abstract: BACKGROUND
  Generation of potent anti-HIV antibody responses in mucosal compartments is a potential requirement of a transmission-blocking HIV vaccine. HIV-specific, functional antibody responses are present in breast milk, and these mucosal antibody responses may play a role in protection of the majority of HIV-exposed, breastfeeding infants. Therefore, characterization of HIV-specific antibodies produced by B cells in milk could guide the development of vaccines that elicit protective mucosal antibody responses.
  
  
  METHODS
  We isolated B cells from colostrum of an HIV-infected lactating woman with a detectable neutralization response in milk and recombinantly produced and characterized the resulting HIV-1 Envelope (Env)-specific monoclonal antibodies (mAbs).
  
  
  RESULTS
  The identified HIV-1 Env-specific colostrum mAbs, CH07 and CH08, represent two of the first mucosally-derived anti-HIV antibodies yet to be reported. Colostrum mAb CH07 is a highly-autoreactive, weakly-neutralizing gp140-specific mAb that binds to linear epitopes in the gp120 C5 region and gp41 fusion domain. In contrast, colostrum mAb CH08 is a nonpolyreactive CD4-inducible (CD4i) gp120-specific mAb with moderate breadth of neutralization.
  
  
  CONCLUSIONS
  These novel HIV-neutralizing mAbs isolated from a mucosal compartment provide insight into the ability of mucosal B cell populations to produce functional anti-HIV antibodies that may contribute to protection against virus acquisition at mucosal surfaces.
authors.affiliation: Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States.
authors.forename: James
authors.initials: J
authors.lastname: Friedman
authors.forename: S Munir
authors.initials: SM
authors.lastname: Alam
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Shen
authors.forename: Shi-Mao
authors.initials: SM
authors.lastname: Xia
authors.forename: Shelley
authors.initials: S
authors.lastname: Stewart
authors.forename: Kara
authors.initials: K
authors.lastname: Anasti
authors.forename: Justin
authors.initials: J
authors.lastname: Pollara
authors.forename: Genevieve G
authors.initials: GG
authors.lastname: Fouda
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Garnett
authors.initials: G
authors.lastname: Kelsoe
authors.forename: Guido
authors.initials: G
authors.lastname: Ferrari
authors.forename: Georgia D
authors.initials: GD
authors.lastname: Tomaras
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: Hua-Xin
authors.initials: HX
authors.lastname: Liao
authors.forename: M Anthony
authors.initials: MA
authors.lastname: Moody
authors.forename: Sallie R
authors.initials: SR
authors.lastname: Permar
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000302:isolation & purification; D057134:Antibodies, Neutralizing / Q000276:immunology* / Q000302:isolation & purification; D001402:B-Lymphocytes / Q000276:immunology*; D003126:Colostrum / Q000166:cytology / Q000276:immunology*; D018985:Epitopes, B-Lymphocyte / Q000235:genetics; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D015483:HIV Antibodies / Q000276:immunology* / Q000302:isolation & purification; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D006801:Humans; D009500:Neutralization Tests; D011247:Pregnancy
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D018985:Epitopes, B-Lymphocyte; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120